Exploring the fate of liposomes in the intestine by dynamic in vitro lipolysis - PubMed (original) (raw)
. 2012 Nov 1;437(1-2):253-63.
doi: 10.1016/j.ijpharm.2012.08.018. Epub 2012 Aug 19.
Affiliations
- PMID: 22939968
- DOI: 10.1016/j.ijpharm.2012.08.018
Exploring the fate of liposomes in the intestine by dynamic in vitro lipolysis
Johannes Parmentier et al. Int J Pharm. 2012.
Abstract
Liposomes are generally well tolerated drug delivery systems with a potential use for the oral route. However, little is known about the fate of liposomes during exposure to the conditions in the gastro-intestinal tract (GIT). To gain a better understanding of liposome stability in the intestine, a dynamic in vitro lipolysis model, which so far has only been used for the in vitro characterisation of other lipid-based drug delivery systems, was applied to different liposomal formulations. Liposome size and phospholipid (PL) digestion were determined as two markers for liposome stability. In addition, the effect of PL degradation on the ability to maintain liposomally incorporated danazol in solution during lipolysis was evaluated in order to address the feasibility of liposomes designed for oral administration. Rate and extend of hydrolysis of PLs mediated by pancreatic enzymes was determined by titration and HPLC. Size of liposomes was determined by dynamic light scattering during incubation in lipolysis medium (LM) and during lipolysis. SPC-based (soy phosphatidylcholine) liposomes were stable in LM, whereas for EPC-3-based (hydrated egg phosphatidylcholine) formulations the formation of aggregates of around 1 μm in diameter was observed over time. After 60 min lipolysis more than 80% of PLs of the SPC-liposomes were digested, but dependent on the liposome concentration only a slight change in size and size distribution could be observed. Although EPC-3 formulations did form aggregates during lipolysis, the lipids exhibited a higher stability compared to SPC and only 30% of the PLs were digested. No direct correlation between liposome integrity assessed by vesicle size and PL digestion was observed. Danazol content in the liposomes was around 5% (mol/mol danazol/total lipid) and hardly any precipitation was detected during the lipolysis assay, despite pronounced lipolytic degradation and change in vesicle size. In conclusion, the tested dynamic in vitro lipolysis model is suitable for the assessment of liposome stability in the intestine. Furthermore, liposomes might be a useful alternative to other lipid based delivery systems for the oral delivery of poorly soluble drugs.
Copyright © 2012 Elsevier B.V. All rights reserved.
Similar articles
- Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium.
Borkar N, Xia D, Holm R, Gan Y, Müllertz A, Yang M, Mu H. Borkar N, et al. Eur J Pharm Sci. 2014 Jan 23;51:204-10. doi: 10.1016/j.ejps.2013.09.022. Epub 2013 Oct 14. Eur J Pharm Sci. 2014. PMID: 24134899 - Development of a high-throughput in vitro intestinal lipolysis model for rapid screening of lipid-based drug delivery systems.
Mosgaard MD, Sassene P, Mu H, Rades T, Müllertz A. Mosgaard MD, et al. Eur J Pharm Biopharm. 2015 Aug;94:493-500. doi: 10.1016/j.ejpb.2015.06.028. Epub 2015 Jul 6. Eur J Pharm Biopharm. 2015. PMID: 26159837 - Morphological observations on a lipid-based drug delivery system during in vitro digestion.
Fatouros DG, Bergenstahl B, Mullertz A. Fatouros DG, et al. Eur J Pharm Sci. 2007 Jun;31(2):85-94. doi: 10.1016/j.ejps.2007.02.009. Epub 2007 Feb 23. Eur J Pharm Sci. 2007. PMID: 17418543 - Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
Dahan A, Hoffman A. Dahan A, et al. J Control Release. 2008 Jul 2;129(1):1-10. doi: 10.1016/j.jconrel.2008.03.021. Epub 2008 Apr 1. J Control Release. 2008. PMID: 18499294 Review. - Impact of gastrointestinal lipolysis on oral lipid-based formulations and bioavailability of lipophilic drugs.
Carrière F. Carrière F. Biochimie. 2016 Jun;125:297-305. doi: 10.1016/j.biochi.2015.11.016. Epub 2015 Nov 29. Biochimie. 2016. PMID: 26607242 Review.
Cited by
- Venturi-based rapid expansion of supercritical solution (Vent-RESS): synthesis of liposomes for pH-triggered delivery of hydrophilic and lipophilic bioactives.
Jash A, Krueger A, Rizvi SSH. Jash A, et al. Green Chem. 2022 Jul 7;24(13):5326-5337. doi: 10.1039/d2gc00877g. Epub 2022 Jun 9. Green Chem. 2022. PMID: 36935900 Free PMC article. - Distribution and Inhibition of Liposomes on Staphylococcus aureus and Pseudomonas aeruginosa Biofilm.
Dong D, Thomas N, Thierry B, Vreugde S, Prestidge CA, Wormald PJ. Dong D, et al. PLoS One. 2015 Jun 30;10(6):e0131806. doi: 10.1371/journal.pone.0131806. eCollection 2015. PLoS One. 2015. PMID: 26125555 Free PMC article. - Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.
Kraft JC, Freeling JP, Wang Z, Ho RJ. Kraft JC, et al. J Pharm Sci. 2014 Jan;103(1):29-52. doi: 10.1002/jps.23773. Epub 2013 Nov 25. J Pharm Sci. 2014. PMID: 24338748 Free PMC article. Review. - Nano-fats for bugs: the benefits of lipid nanoparticles for antimicrobial therapy.
Thorn CR, Thomas N, Boyd BJ, Prestidge CA. Thorn CR, et al. Drug Deliv Transl Res. 2021 Aug;11(4):1598-1624. doi: 10.1007/s13346-021-00921-w. Epub 2021 Mar 5. Drug Deliv Transl Res. 2021. PMID: 33675007 Review. - Bolalipid-Doped Liposomes: Can Bolalipids Increase the Integrity of Liposomes Exposed to Gastrointestinal Fluids?
Müller S, Gruhle K, Meister A, Hause G, Drescher S. Müller S, et al. Pharmaceutics. 2019 Dec 3;11(12):646. doi: 10.3390/pharmaceutics11120646. Pharmaceutics. 2019. PMID: 31816937 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources